Oncologia
Revisão | Lesão renal aguda em pacientes críticos com câncer.
29 Mar, 2022 | 14:55h
Comentário no Twitter
Advances in cancer therapy have improved patient survival; however, AKI is common in patients with cancer. This Review highlights the epidemiology of AKI in critically ill patients with cancer, risk factors for AKI, & common pathologies linked to therapies https://t.co/AVUvGCqqwh pic.twitter.com/1GdM3P0h3j
— CJASN (@CJASN) March 28, 2022
Revisão | A ascensão da imagem fotoacústica na oncologia clínica.
29 Mar, 2022 | 14:34hThe emerging role of photoacoustic imaging in clinical oncology – Nature Reviews Clinical Oncology (se o acesso a este link for pago, tente este)
Comentário no Twitter
In a Review now published online, Li Lin and Lihong Wang discuss the clinical applications of photoacoustic imaging in oncology research and practice https://t.co/ENESZ0ibOI pic.twitter.com/oukxtHvzsf
— NatureRevClinOncol (@NatRevClinOncol) March 24, 2022
Estudo randomizado | Transtuzumab Deruxtecan vs. trastuzumabe Entansina para câncer de mama.
29 Mar, 2022 | 14:00hTrastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer – New England Journal of Medicine (link para o resumo – $ para o texto completo)
Comentário: Trastuzumab Deruxtecan Ups PFS in HER2+ Metastatic Breast Cancer – HealthDay
Comentário no Twitter
In patients with metastatic HER2+ breast cancer that progressed after primary therapy, treatment with trastuzumab deruxtecan resulted in a higher response rate and longer progression-free survival than trastuzumab emtansine. https://t.co/R5suUeMLgE pic.twitter.com/yMiGrJw71U
— NEJM (@NEJM) March 24, 2022
Revisão | Preparo para terapia com células T CAR: seleção do paciente, terapias intermediárias e linfodepleção.
29 Mar, 2022 | 13:58hPreparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion – Nature Reviews Clinical Oncology (se o acesso a este link for pago, tente este)
Comentário no Twitter
In a new Review now online, @abouelem and co-authors discuss the preparation and management of patients with cancer before #CARTcells, an area in which evidence on optimal conditions needs to grow https://t.co/Sb6rgcOTTJ pic.twitter.com/wjRrPDpoT7
— NatureRevClinOncol (@NatRevClinOncol) March 23, 2022
Estudo de coorte | Associação de linfedema de membro inferior com função física e atividades de vida diária entre idosos sobreviventes de câncer colorretal, endometrial e ovariano.
29 Mar, 2022 | 13:53hComentários:
Lower-Extremity Lymphedema Common in Older, Female Cancer Survivors – HealthDay
Comentário no Twitter
Cohort study found nearly 1/3 of older female survivors of #ColorectalCancer, #EndometrialCancer, or #OvarianCancer have lower-extremity lymphedema (LEL), which is associated with worse physical function and needing assistance with ADLs. https://t.co/806Tt88TuV
— JAMA Network Open (@JAMANetworkOpen) March 9, 2022
Estudo randomizado | Efeito da quimioterapia de indução com paclitaxel, cisplatina e capecitabina vs. cisplatina e fluorouracil na sobrevida livre de recorrência para pacientes com carcinoma nasofaríngeo estágios IVA a IVB.
29 Mar, 2022 | 13:49hEffect of Induction Chemotherapy With Paclitaxel, Cisplatin, and Capecitabine vs Cisplatin and Fluorouracil on Failure-Free Survival for Patients With Stage IVA to IVB Nasopharyngeal Carcinoma: A Multicenter Phase 3 Randomized Clinical Trial – JAMA Oncology (link para o resumo – $ para o texto completo)
Comentário: Triplet Induction Regimen Bests Doublet for Nasopharyngeal Carcinoma — Three drugs reduced risk of disease failure, but longer follow-up needed to assess OS – MedPage Today (necessário cadastro gratuito)
Comentário no Twitter
Phase 3 randomized trial of paitents with stage IVA to IVB nasopharyngeal carcinoma shows that induction chemotherapy w 2 cycles of paclitaxel/cisplatin/capecitabine improved failure-free survival vs. cisplatin/5-FU before concurrent chemoradiation. https://t.co/YYEvFsTxgd pic.twitter.com/7qbSXLWCE1
— JAMA Oncology (@JAMAOnc) March 24, 2022
Adoçantes artificiais e risco de câncer: resultados de estudo de coorte de base populacional do NutriNet-Santé.
25 Mar, 2022 | 16:11hComentários:
Sweeteners may be linked to increased cancer risk – new research – The Conversation
Expert reaction to observational study of sweeteners and cancer risk – Science Media Centre
Revisão JACC | A função da cardioproteção contra a cardiotoxicidade da terapia oncológica.
25 Mar, 2022 | 15:55hRevisão | Tratamento cirúrgico do câncer gástrico.
25 Mar, 2022 | 15:52hSurgical Management of Gastric Cancer: A Review – JAMA Surgery (gratuito por tempo limitado)